Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer

6/3/24 8:38:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYCC alert in real time by email

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma -

BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.

Get the next $CYCC alert in real time by email

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer

Chat with this insight

Recent Analyst Ratings for $CYCC

$CYCC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc. (Amendment)

$CYCC Press Releases

Fastest customizable press release news feed in the world

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

$CYCC Leadership Updates

Live Leadership Updates

$CYCC Financials

Live finance-specific insights

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

$CYCC SEC Filings

Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$CYCC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$CYCC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Rombotis Spiro George bought $20,122 worth of shares (6,070 units at $3.31), increasing direct ownership by 10% to 68,658 units (SEC Form 4)

Mcbarron Paul bought $6,252 worth of shares (1,886 units at $3.31), increasing direct ownership by 6% to 33,378 units (SEC Form 4)

Schwartz Brian was granted 12,500 shares, increasing direct ownership by 462% to 15,205 units (SEC Form 4)

Rombotis Spiro George bought $20,122 worth of shares (6,070 units at $3.31), increasing direct ownership by 10% to 68,658 units (SEC Form 4)

Mcbarron Paul bought $6,252 worth of shares (1,886 units at $3.31), increasing direct ownership by 6% to 33,378 units (SEC Form 4)

$CYCC Market Insights

Live Market Insights

Cyclacel Pharmaceuticals to Receive European Patent Grant for Novel Pharmaceutical Compositions of Plogosertib; Patent Provides Exclusivity Until August 2040; Applications in Other Jurisdictions Pending

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

$CYCC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer resumed coverage on Cyclacel Pharma with a new price target

Oppenheimer initiated coverage on Cyclacel Pharmaceuticals with a new price target

Recent Analyst Ratings for
$CYCC

$CYCC
Large Ownership Changes

$CYCC
Press Releases

$CYCC
Leadership Updates

$CYCC
Financials

$CYCC
SEC Filings

$CYCC
Insider Purchases

$CYCC
Insider Trading

$CYCC
Market Insights

$CYCC
Analyst Ratings